Peripheral blood stem cell transplants (PBSCT) from unrelated donors (n = 37) were compared with bone marrow transplants (BM, bone marrow group, n = 37) in a matched pair analysis. Ten patients (2, class 1) in the alloPBSCT group and seven patients (2, class 1) in the BM group had one HLA locus mismatch donor, respectively. The following factors were matched: HLAcompatibility, diagnosis, disease stage, age and gender. The median age in the PBSC group was 37 years (19-56, excluding one 6-year-old child) and in the BM group 37 years (18-53). The BM group consisted of 12 females and 25 males, 17 females and 20 males were in the PBSC group. Twelve patients in the BM and 11 patients in the PBSC group were diagnosed with AML; 7/7, ALL; 15/15, CML; 2/3, MDS; 1/1, NHL. Thirty-four (14/20) of the 74 patients (45%) were considered as high risk patients. The conditioning regimen was BU/CY for standard risk patients with myeloid diseases (31 patients) and TBI/CY for ALL and NHL patients (36 patients); six patients received intensified conditioning with VP-16 (2 patients), thiotepa (2 patients) or melphalan (1 patient). The GVHD prophylaxis regimen was used according to the Seattle protocol. DFS was 51% (19 patients) with a median of 352 days and 59% (21 patients) with a median of 760 days, in PBSC and BM transplants, respectively. The median time to leukocyte engraftment in PBSC patients was 14 days (range 6-26 days) and in the BM group 19 days (range 9-29 days; P Ͻ 0.02). The time of platelet engraftment did not differ significantly between the groups. The incidence of grade II-IV acute GVHD was 40% (four patients died, 13%) in the PBSC group and 20% (three patients died, 8%) in the BM group, respectively (P Ͻ 0.05, log-rank). No signs of aGVHD were found in 19% of the patients in the PBSC and 27% in the BM group. Our results indicate that allogeneic PBSCT does lead to a significantly faster leukocyte engraftment. The significant increase with regard to the incidence and shorter time of onset of severe aGVHD in PBSC patients, compared to marrow transplant patients, need to be confirmed in a randomised trial. Bone Marrow Transplantation (2000) 25, Suppl. 2, S27-S31.
Since 1989, peripheral blood stem cells (PBSC) after stimulation with granulocyte-stimulating factor (G-CSF) have been increasingly used as an alternative to hematopoietic stem cells derived from bone marrow in related donor transplants. 1 By 1996, the EBMT had already published data on more than 1000 transplants using PBSCT as grafts. 2 The potential advantages of PBSC for allogeneic transplants are numerous. In patients with PBSC transplants a more rapid engraftment could be demonstrated in comparison to grafts derived from BM. [3] [4] [5] Published data indicated that PBSC transplantation is associated with a reduction of antibiotics, shortened hospital stays and a lower 200-day mortality. 4, 5 It has also been suggested that immunological recovery is more rapid following allogeneic PBSC transplants. 6 Typical PBSC products contain three to four times more CD34 ϩ cells and also 20 times higher T cell levels when compared to a typical marrow product. 7 However, the main concern with allogeneic PBSC transplantation might be the increased incidence and severity of graft-versus-host disease (GVHD). So far an increased incidence or severity of acute GVHD following PBSC transplants [3] [4] [5] 8 has not been described, however, an increased incidence and severity with regard to chronic GVHD has been reported. 9, 10 PBSC may also be advantageous for allogeneic donors. Only 3-7% of all donors experienced complications with regard to the stimulation by G-CSF. Apheresis is carried out in an outpatient setting. 11, 12 In the last 2 years only a few patients received PBSC from an unrelated donor, 13, 14 in order to investigate the impact of PBSC in MUD transplant we started with unrelated allogeneic PBSC transplants in 1997. Thirty-seven patients were transplanted at our center. We are reporting our experience with allogeneic PBSC transplants and compared our results with transplants using bone marrow cells.
Patients and methods

Patients
Patients were included in this study after approved informed consent was obtained from the donor and recipient. Transplants were performed between January 1995 and May 1999 in our center. Patient and donor characteristics are given in Table 1 . 
Informed consent
The study was approved by our institutional review board (IRB) and also approved by the Ethics Committee at the Landesärztekammer Rheinland-Pfalz.
Bone marrow control group
All 37 patients were transplanted at our institution from January 1995 to May 1999 with PBSC from unrelated donors. Each patient receiving an unrelated PBSC was matched with a patient, who received a BM from an unrelated donor. The following prognostic factors were matching: diagnosis, disease stage, age, HLA-compatibility and GVHD prophylaxis.
Donors
Twenty-seven donors of PBSC were HLA-identical, two had a class I locus mismatch, one with a locus-A mismatch, one with a locus B-mismatch, and eight donors had one DR-locus mismatch, respectively. Thirty donors of bone marrow were HLA-identical, two had a B-locus mismatch and five a DR-locus mismatch. HLA-typing was done by serology for class I, and using polymerase chain reactionsingle stranded polymorphism (PCR-SSP) for class II. All PBSC donors received G-CSF (Rhone-Poulenc Rorer, Lyon, France, or Amgen, Thousand Oaks, CA, USA). The G-CSF dose ranged from 7 to 12 g/kg, administered subcutaneously twice daily. G-CSF was administered for 4 days in five donors, 5 days in 27 donors, and for 6 days in five donors. One leukapheresis was performed in 15 donors and two in 22 donors. The donors experienced bone pain in most cases, which was relieved by paracetamol.
Treatment regimens
The conditioning regimen was busulfan (16 mg/kg) orally administered over 4 days and cyclophosphamide (60 mg/kg/day i.v.), administered on 2 consecutive days for standard risk patients with myeloid diseases (31 patients). ALL and NHL patients (n = 36) received 2.25 Gy TBI twice daily for 3 consecutive days (13.5 Gy) and cyclophosphamide (60 mg/kg/day i.v.) for 2 consecutive days; six patients with refractory leukemias received an intensified conditioning regimen with BU/CY and VP-16 (60 mg/kg/day i.v.) once (two patients) or thiotepa (10 mg/kg i.v.) once (two patients) or melphalan (140 mg/m 2 i.v.) once (one patient). GVHD prophylaxis regimen consisted of prednisolone from day 7 to day 14 at 0.5 mg/kg/day i.v., followed by 1.0 mg/kg/day from day 15 and then tapered; cyclosporin A (10 mg/kg/day) from day Ϫ3 and methotrexate (15 mg/m 2 ) were given on day 1 followed by 10 mg/m 2 on days 3 and 6. CD34 ϩ cell selection for T cell depletion using immunomagnetic beads (Isolex 300 SA, Baxter, Deerfield, IL, USA) was performed in one patient.
Evaluation
CD34
ϩ , CD3 ϩ , and CD56 ϩ cells were determined in BM or leukapheresis product by flow cytometry, as previously described. 15 Engraftment was assessed according to published criteria. 7 Briefly, myeloid engraftment was defined as the first of 3 consecutive days when the absolute neutrophil count was higher than 0.5 ϫ 10 9 /1. Platelet engraftment was defined as the first of 7 consecutive days when the platelet count exceeded 20 ϫ 10 9 /1 without transfusions. Acute GVHD was graded according the standard criteria. 16 Chronic GVHD was assessed in patients alive after day 100. 17 Transplant-related mortality (TRM) was defined as death in absence of relapse. Relapse was diagnosed from BM specimens taken on day 30, day 100 and every 100 days regularly or when clinically indicated.
Statistics
The median follow-up is 558 days (76-1860 days), corresponding to 18.6 months (2.5-62 months). The KaplanMeier method followed by log-rank test (Mantel-Haenszel) was used to estimate the probability of overall and diseasefree survival, acute GVHD, myeloid and platelet engraftment. The Mann-Witney U-test was used to compare cell yield, time to engraftment, transfusions, and time of hospitalisation. 18 Patients surviving more than 30 days were included in the analysis of acute GVHD. A minimum of 100 days of follow-up was the criterion for chronic GVHD.
Results
Peripheral blood stem cell (PBSC) transplants from unrelated donors (n = 37) were compared with bone marrow (n = 37) with regard to the incidence and severity of acute and chronic GVHD, time to engraftment and infection complications.
Characteristics of grafts
A significant difference between cell count in grafts was demonstrated between the BM and PBSC groups with regard to the number of nucleated cells, CD34 ϩ , CD3 ϩ , and CD56 ϩ cells as depicted in Table 2 .
Engraftment
Thirty-two (87%) patients in the PBSC group and 36 (97.5%) patients in the BM group showed myeloid and 28 (75%) and 26 (70%) platelet engraftment. Late graft failure was observed in one female after PBSC infusion and one male after bone marrow transplantation. The median time to leukocyte engraftment was 14.5 days (8-35 days) in the PBSC group and 19 days (10-33 days) in the BM group. Time to ANC greater than 0.5 ϫ 10 9 /1 was significantly faster in the PBSC compared to the BM group (P = 0.018). The time period to platelet counts 20 ϫ 10 9 /1 tended to be prolonged in patients receiving a BM in comparison to PBSC (median 14 days (12-78 days) and 19 days (19-100 days), P = 0.66). The PBSC group required fewer platelet transfusions, however the difference was not significant. The median time of inpatient treatment was 48.5 in the PBSC group and 45.5 days in the BM group, which again is not statistically different.
Relapse rate and transplant-related mortality (TRM)
The overall TRM and relapse rate did not differ between the two groups. Eight patients of the BM group and seven patients of the PBSC group relapsed and six of them died. One of them is in complete remission 1 year after chemotherapy followed by donor lymphocyte infusion. Moreover, five patients of the BM group (two fungal infections, three herpes virus infection) and two of the PBSC group (toxoplasmic encephalitis, bacterial pneumonia) died due to severe infections. GVHD and multiorgan failure as cause of death were observed in the PBSC group (four and two patients vs four and one patient, respectively), however the difference is not significant. Bone Marrow Transplantation Figure 1 Cumulative incidence of grades II-IV acute GVHD after stem cell transplantation of unrelated PBSC (38%) or BM (20%; P = 0.046).
Incidence of acute GVHD and chronic GVHD
We demonstrated a significant difference (log-rank test, P = 0.046) on incidence and time of onset of acute GVHD II-IV between the two groups ( Figure 1 ). Twelve patients suffered from acute GVHD grade III-IV in the PBSC group (four died) and eight (four died) in the BM group, respectively. The chi-square test detected no significant difference in GVHD incidence between the two groups. Eight patients of the PBSC group and nine patients of the BM group developed acute GVHD grade 1. No differences have been observed regarding the incidence and time of onset of chronic GVHD between the two groups; 50% of patients of both groups developed chronic GVHD (Figure 2 ).
Disease-free survival, overall survival
The median disease-free survival was 365 days in the PBSC and 687 days in the BM group (P = 0.63; log-rank test). Two years after transplant 51.3% PBSC patients and 59.5% BM patients are still alive. The median overall survival was 673 days in the BM group and 328 days in the PBSC group ( Figure 3 , P = 0.33; log-rank test). 
Discussion
We compared the clinical outcome of patients transplanted with either bone marrow cells or peripheral blood derived stem cells. Thirty-seven patients received a peripheral blood stem transplant from an unrelated donor; thirty-seven out of 175 patients, who received a bone marrow transplant, were matched with regard to gender, age, diagnosis and HLA-matching. Engraftment was significantly faster in the PBSC group compared to the BM group. The shortened time of neutropenia did not lead to a lower incidence of infections; any complications might be explained by the low number of patients with documented infections in both groups. The time to platelet engraftment did not differ in both groups contrasting the results published in sibling transplants. 3, 19 We observed a significantly higher incidence and shorter time period of onset of acute GVHD in patients receiving a PBSC transplant, which is in contrast again to the incidence of acute GVHD reported for allogeneic PBSC transplants with HLA-identical sibling donors. 8, 13, 19 In our retrospective multicenter analysis published recently, 19 we did not observe a higher incidence of severe acute GVHD (30% vs 20%; P = NS). Our data described here demonstrating a significantly higher acute GVHD incidence in the PBSC group are different due to the grade of HLA-matching, ie the number of patients with donors, who were not HLA-identical (10 in the PBSC group and seven in the BM group). Since there are differences with regard to the clinical outcome of patients undergoing stem cell transplantation either by using bone marrow or peripheral blood stem cells in the discussed multicenter and single center study it becomes obvious that the question with regard to the incidence and also the severity of acute and chronic GVHD has to be addressed in a prospective randomized clinical study comparing MUD transplants by using either bone marrow or peripheral blood stem cells.
